Compare IRMD & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | MNMD |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | N/A |
| Metric | IRMD | MNMD |
|---|---|---|
| Price | $99.25 | $14.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $72.00 | $30.33 |
| AVG Volume (30 Days) | 89.1K | ★ 2.2M |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $80,511,268.00 | N/A |
| Revenue This Year | $15.17 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $59.98 | ★ N/A |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $47.48 | $4.70 |
| 52 Week High | $100.39 | $15.29 |
| Indicator | IRMD | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 60.38 |
| Support Level | $97.39 | $13.06 |
| Resistance Level | $100.01 | $15.29 |
| Average True Range (ATR) | 2.31 | 0.84 |
| MACD | -0.23 | 0.10 |
| Stochastic Oscillator | 83.45 | 60.49 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).